Comparing SG&A Expenses: TG Therapeutics, Inc. vs ImmunityBio, Inc. Trends and Insights

SG&A Expenses: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing expenses is crucial for survival and growth. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent biotech firms: TG Therapeutics, Inc. and ImmunityBio, Inc., from 2014 to 2023.

ImmunityBio, Inc.: A Rollercoaster Ride

ImmunityBio's SG&A expenses have shown significant fluctuations over the years. Starting at a modest $4.3 million in 2014, they skyrocketed to a peak of $226 million in 2015, reflecting a strategic expansion phase. Despite a dip in subsequent years, expenses stabilized around $130 million by 2023, indicating a more controlled growth strategy.

TG Therapeutics, Inc.: Steady Growth

In contrast, TG Therapeutics maintained a more consistent trajectory. Beginning with $24.5 million in 2014, their expenses peaked at $152 million in 2021, marking a 520% increase over the decade. This steady rise suggests a gradual scaling of operations, aligning with their long-term growth objectives.